| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | P80; IL1R; IL1RA; CD121A; D2S1473; IL-1R-alpha |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human IL1R1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4篇关于IL1R1抗体的代表性文献摘要整理：
---
1. **文献名称**: *Targeting interleukin-1 in inflammatory disease*
**作者**: Dinarello, C.A.
**摘要**: 综述了IL-1信号通路在自身炎症性疾病(如类风湿性关节炎)中的作用，并探讨了IL1R1抗体(如Anakinra)通过阻断IL-1α/β与受体的结合，抑制下游炎症反应的机制及临床应用潜力。
2. **文献名称**: *A randomized trial of IL1R1 antibody (rilonacept) for cryopyrin-associated periodic syndromes*
**作者**: Hoffman, H.M., et al.
**摘要**: 报道了一项针对冷吡啉相关周期性综合征(CAPS)患者的临床试验，显示IL1R1拮抗剂rilonacept能显著降低炎症标志物(如CRP)和症状发作频率，验证了IL1R1靶向治疗的有效性。
3. **文献名称**: *IL-1 signaling in tumor microenvironment promotes resistance to anti-PD-1 therapy*
**作者**: Apte, R.N., et al.
**摘要**: 研究发现肿瘤微环境中IL-1通过IL1R1激活髓系免疫细胞，抑制T细胞功能;使用IL1R1抗体可增强抗PD-1疗法的抗肿瘤效果，为联合免疫治疗提供了新策略。
4. **文献名称**: *IL1R1 blockade mitigates neuroinflammation and glioblastoma progression*
**作者**: Herrera, M., et al.
**摘要**: 在胶质母细胞瘤模型中，IL1R1抗体抑制了IL-1β介导的NF-κB通路活化，减少肿瘤相关炎症因子的释放，延缓了肿瘤生长并改善小鼠生存率。
---
以上文献覆盖了IL1R1抗体在自身免疫病、肿瘤治疗等领域的研究进展。如需具体文章链接或扩展内容，可进一步补充关键词或研究场景!
Interleukin-1 receptor type 1 (IL1R1) is a key transmembrane receptor responsible for mediating the biological effects of interleukin-1 (IL-1) family cytokines, including IL-1α and IL-1β. These cytokines are central regulators of inflammation, immune responses, and tissue homeostasis. IL1R1 binds to IL-1 ligands and recruits the IL-1 receptor accessory protein (IL-1RAcP) to form a signaling complex, activating downstream pathways such as NF-κB and MAPK, which drive pro-inflammatory gene expression. Dysregulation of IL-1 signaling is implicated in autoimmune diseases (e.g., rheumatoid arthritis), inflammatory disorders (e.g., gout), and certain cancers.
IL1R1-targeting antibodies are therapeutic agents designed to block IL-1/IL1R1 interactions, thereby suppressing excessive inflammation. Monoclonal antibodies (mAbs) against IL1R1. such as Anakinra (a recombinant IL-1 receptor antagonist) and later-developed biologics, have shown efficacy in clinical trials for conditions like cytokine release syndrome and COVID-19-related hyperinflammation. These antibodies typically function by competitively inhibiting IL-1 binding or disrupting receptor complex formation. Some are engineered to enhance specificity or prolong half-life through humanization or Fc modifications. Recent research also explores bispecific antibodies or combination therapies to improve outcomes in diseases with complex inflammatory pathways, such as atherosclerosis or tumor microenvironment modulation. Challenges include balancing immunosuppression with infection risks and optimizing tissue-specific targeting. Overall, IL1R1 antibodies represent a critical tool in precision immunomodulation.
×
